| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2017-11-21 17:43:13 UTC |
|---|
| Update Date | 2022-03-07 03:18:14 UTC |
|---|
| HMDB ID | HMDB0240243 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Homochlorcyclizine |
|---|
| Description | Homochlorcyclizine, also known as curosajin or homoclomine, belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. In humans, homochlorcyclizine is involved in the homochlorcyclizine h1-antihistamine action pathway. Homochlorcyclizine is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review very few articles have been published on Homochlorcyclizine. |
|---|
| Structure | CN1CCCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1 InChI=1S/C19H23ClN2/c1-21-12-5-13-22(15-14-21)19(16-6-3-2-4-7-16)17-8-10-18(20)11-9-17/h2-4,6-11,19H,5,12-15H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| Curosajin | HMDB | | (±)-homochlorcyclizine | HMDB | | Homochlorocyclizine | HMDB | | Homoclomine | HMDB | | Homodamon | HMDB | | Homorestar | HMDB | | Lysilan | HMDB | | N-(p-Chlorobenzhydryl)-n'-methylhomopiperazine | HMDB | | NSC 25132 | HMDB | | SA 97 | HMDB | | Sankumin | HMDB | | Wicron | HMDB | | Homochlorcyclizine HCL | HMDB | | Homochlorocyclizine hydrochloride | HMDB | | Homochlorocyclizine monohydrochloride | HMDB | | 1-((4-Chlorophenyl)phenylmethyl)hexahydro-4-methyl-1H-1,4-diazepine | HMDB | | Homochlorcyclizine | HMDB, MeSH |
|
|---|
| Chemical Formula | C19H23ClN2 |
|---|
| Average Molecular Weight | 314.86 |
|---|
| Monoisotopic Molecular Weight | 314.1549764 |
|---|
| IUPAC Name | 1-[(4-chlorophenyl)(phenyl)methyl]-4-methyl-1,4-diazepane |
|---|
| Traditional Name | homochlorcyclizine |
|---|
| CAS Registry Number | 848-53-3 |
|---|
| SMILES | CN1CCCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1 |
|---|
| InChI Identifier | InChI=1S/C19H23ClN2/c1-21-12-5-13-22(15-14-21)19(16-6-3-2-4-7-16)17-8-10-18(20)11-9-17/h2-4,6-11,19H,5,12-15H2,1H3 |
|---|
| InChI Key | WEUCDJCFJHYFRL-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Diphenylmethanes |
|---|
| Direct Parent | Diphenylmethanes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Diphenylmethane
- 1,4-diazepane
- Chlorobenzene
- Diazepane
- Halobenzene
- Aralkylamine
- Aryl chloride
- Aryl halide
- Tertiary aliphatic amine
- Tertiary amine
- Organoheterocyclic compound
- Azacycle
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Organic nitrogen compound
- Amine
- Hydrocarbon derivative
- Organopnictogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.84 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.0084 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.62 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 660.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 259.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 171.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 189.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 101.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 400.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 451.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 859.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 797.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 263.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1114.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 224.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 343.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 488.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 376.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 11.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Homochlorcyclizine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Homochlorcyclizine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 10V, Positive-QTOF | splash10-014i-0029000000-8a61986cf6d60bf81cda | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 20V, Positive-QTOF | splash10-0gb9-3096000000-959bed2bb20cae706198 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 40V, Positive-QTOF | splash10-0udl-9240000000-e1c510f4600b8a191aa9 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 10V, Negative-QTOF | splash10-03di-0009000000-dc2748d860fa60954b1d | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 20V, Negative-QTOF | splash10-03di-0159000000-65f5c34b0b35e0ac26b6 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 40V, Negative-QTOF | splash10-02fx-5490000000-940d537678147878c1c3 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 10V, Positive-QTOF | splash10-014i-0039000000-e5538a12567efbc3dfa8 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 20V, Positive-QTOF | splash10-0uxr-0094000000-a3c4471119f072f6e962 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 40V, Positive-QTOF | splash10-0udi-1290000000-05fb262b2cc10b1e2916 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 10V, Negative-QTOF | splash10-03di-0009000000-c54768588510ddbc9bef | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 20V, Negative-QTOF | splash10-0ik9-0089000000-970bf509629d7033eebd | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Homochlorcyclizine 40V, Negative-QTOF | splash10-0ik9-1491000000-b2affbdb4464c5870a0d | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Suzuki A, Yasui-Furukori N, Mihara K, Kondo T, Furukori H, Inoue Y, Kaneko S, Otani K: Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. [PubMed:12657913 ]
|
|---|